Adults who misuse opioids: Substance abuse treatment use and perceived treatment need

References

• Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017. Available at: https://www.samhsa.gov/data/sites/default/files/…2016/NSDUH-DetTabs-2016.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Opioid Overdose 2017; Available at: https://www.cdc.gov/drugoverdose/epidemic/index.html
   Google Scholar
• Seth P, Rudd R, Noonan R, Haegerich T. Quantifying the epidemic of prescription opioid overdose deaths. Am J Public Health. 2018;108(4):e1–e3.
   Web of Science ®Google Scholar
• Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999-2016. NCHS Data Brief, no 294. 2017. Hyattsville, MD: National Center for Health Statistics. Available at: https://www.cdc.gov/nchs/data/databriefs/db294.pdf
   Google Scholar
• Wu L-T, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127. doi:10.1016/j.drugalcdep.2016.10.015
   PubMed Web of Science ®Google Scholar
• Romo E, Ulbricht CM, Clark RE, et al. Correlates of specialty substance use treatment among adults with opioid use disorders. Addict Behav. 2018;86:96–103. doi:10.1016/j.addbeh.2018.03.012
   PubMed Web of Science ®Google Scholar
• Wollschlaeger BA, Willson TM, Montejano LB, et al. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. J Opioid Manag. 2017;13(4):207–220.
   PubMedGoogle Scholar
• Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2005-2015. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-91, HHS Publication No. (SMA) 17-5037. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017. Available at: https://www.samhsa.gov/data/sites/default/files/2015_Treatment_Episode_Data_Set_National/2015_Treatment_Episode_Data_Set_National.html#Chp2
   Google Scholar
• Inter-university Consortium for Political and Social Research. National Survey on Drug Use and Health, 2015. ICPSR50011-v1. On behalf of the United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality, 2016. doi:10.3886/ICPSR50011.v1
   Google Scholar
• Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health Public Use File Codebook. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
   Google Scholar
• Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health: Methodological Summary and Definitions. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV). Washington D.C.: American Psychiatric Association; 1994.
   Google Scholar
• Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–1127.
   PubMedGoogle Scholar
• Novak SP, Colpe LJ, Barker PR, et al. Development of a brief mental health impairment scale using a nationally representative sample in the USA. Int J Methods Psychiatr Res. 2010;19(S1):49–60.
   PubMed Web of Science ®Google Scholar
• Rehm J, Üstün TB, Saxena S, et al. On the development and psychometric testing of the WHO screening instrument to assess disablement in the general population. Int J Method Psychiat Res. 1999;8(2):110–123.
   Google Scholar
• Allison P. When Can You Safely Ignore Multicollinearity? 2015. Available at: https://statisticalhorizons.com/multicollinearity
   Google Scholar
• Schepis TS, Teter CJ, Simoni-Wastila L, McCabe SE. Prescription tranquilizer/sedative misuse prevalence and correlates across age cohorts in the US. Addict Behav. 2018;87:24–32.
   PubMed Web of Science ®Google Scholar
• Lipari RN, Williams M, Van Horn SL. Why Do Adults Misuse Prescription Drugs? The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017.
   Google Scholar
• Krawczyk N, Picher CE, Feder KA, et al. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff (Millwood). 2017;36(12):2046–2053.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Gryczynski J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013;103(5):917–922.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–27.
   PubMed Web of Science ®Google Scholar
• Connery HS. Medication-assisted treatment of opioid use disorder: review of evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.
   PubMed Web of Science ®Google Scholar
• Saloner B, Stoller KB, Barry CL. Medicaid coverage for methadone maintenance and use of opioid agonist therapy in specialty addiction treatment. PS. 2016;67(6):676–679.
   Google Scholar
• McKenna RM. Treatment use, sources of payment, and financial barriers to treatment among individuals with opioid use disorder following the national implementation of the ACA. Drug Alcohol Depend. 2017;179:87–92. doi:10.1016/j.drugalcdep.2017.06.028
   PubMed Web of Science ®Google Scholar
• Saloner B, Levin J, Chang H-Y, et al. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid expansion. JAMA Network Open. 2018;1(4):e181588–e181588. doi:10.1001/jamanetworkopen.2018.1588
   PubMed Web of Science ®Google Scholar
• Schiff DM, Drainoni ML, Weinstein ZM, et al. A police-led addiction treatment referral program in Gloucester, MA: implementation and participants' experiences. J Subst Abuse Treat. 2017;82:41–47.
   PubMed Web of Science ®Google Scholar
• Naeger S, Mutter R, Ali MM, et al. Post-discharge treatment engagement among patients with an opioid-use disorder. J Subst Abuse Treat. 2016;69:64–71.
   PubMed Web of Science ®Google Scholar
• Marie BS, Sahker E, Arndt S. Referrals and treatment completion for prescription opioid admissions: five years of national data. J Subst Abuse Treat. 2015;59:109–114.
   PubMed Web of Science ®Google Scholar